C H A P T E R
71 Treatment of Autoimmune Disease: Established Therapies Benedict K. Tiong, Bevra H. Hahn and Thanda Aung David Geffen School of Medicine, Division of Rheumatology, University of California Los Angeles, Los Angeles, CA, United States
O U T L I N E Principles of Immune Suppression
Nonspecific Antiinflammatory Drugs Nonsteroidal Antiinflammatory Drugs Glucocorticoids
1419 1419 1419
Established Treatments of Rheumatic Diseases Antimalarials Sulfasalazine Leflunomide Methotrexate Cyclophosphamide Mycophenolate Mofetil (Cellcept) Azathioprine (Imuran) Calcineurin Inhibitors: Cyclosporin A, Tacrolimus, and Voclosporin
1420 1420 1420 1421 1421 1422 1423 1423
Biologic Agents Cytokine-Targeted Therapies Tumor Necrosis Factor Inhibitors Tocilizumab (Anti-IL6R: Actemra)
1424 1424 1425 1425
IL-1 Antagonists Secukinumab (Anti-IL17A: Cosentyx) Ustekinumab (Anti-p40 for IL-12 and IL-23 Signaling: Stelara) B-Cell-Targeted Therapies Rituximab (Rituxan) Belimumab (Anti-BLyS: Benlysta) T-Cell-Targeted Therapies
Other Treatment Options Apremilast (Otezla) Tofacitinib (Inhibitor of Janus Kinase Activation Pathway: Xeljanz)
Comment Regarding Costs of Therapies: Biosimilars
Moving Toward More Biological and Molecular Therapies
1426 1427 1427 1427 1427
Rapid advances in immunology and greater understanding of disease etiology and pathogenesis have made the treatment of autoimmune diseases a dynamic and swiftly evolving field. Established therapies such as glucocorticoids (GCs), nonspecific immunosuppressive agents, and disease-modifying rheumatoid drugs (DMARD) are being supplemented or replaced by newer, more targeted biologic and molecular therapies. Progress in elucidation of basic mechanisms of autoimmune diseases has led to rapid development of targets on antigen-presenting cells (APCs), T/B lymphocytes, cytokines, and costimulatory molecules. In addition, improved measures of defining clinical response and identification of biomarkers reflecting clinical outcomes and prognosis have accelerated the development of treatment options for autoimmune diseases. The goal of this
The Autoimmune Diseases, 6th. DOI: https://doi.org/10.1016/B978-0-12-812102-3.00071-3
Copyright © 2020 Elsevier Inc. All rights reserved.
71. TREATMENT OF AUTOIMMUNE DISEASE: ESTABLISHED THERAPIES
chapter is to review established therapies of autoimmune diseases, with a focus on rheumatic diseases. We will highlight traditional therapies that form the foundation of current clinical practice (see Table 71.1), while laying out a context for which newer biologic and molecular targets are now incorporated into the current standard of care. TABLE 71.1 Drug
Established Immunosuppressive Treatments for Autoimmune Rheumatic Diseases Primary mechanism of action
CONVENTIONAL DMARDS Antimalarials
Inhibition of TLR-3/7, raising of lysozyme pH affecting antigen processing
Retinopathy and gray skin/nails discoloration. Rarely headache, pruritus, rash, neuropathy, corneal deposition, peripheral myopathy, cardiomyopathy
Systemic lupus erythematosus, rheumatoid arthritis, juvenile idiopathic arthritis, Sjogren’s, juvenile dermatomyositis, palindromic rheumatism
Inhibition of prostaglandin synthesis and cylcooxygenase, inhibition of NFκB transcription, reduction of TNF, suppression of B cells
Elevated liver enzymes, leukopenia, agranulocytosis, megaloblastic anemia, oligospermia, sperm dysmotility, GI or CNS side effects
Inflammatory bowel disease (ulcerative colitis), mild rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis
Inhibits dihydroorotate dehydrogenase, affecting de novo pyrimidine synthesis
Elevated liver enzymes, diarrhea, rash, hair loss, hypertension, interstitial pneumonitis, class X teratogen
Inhibits dihydrofolate reductase, interfering with purine and pyrimidine metabolism and amino acid synthesis
Elevated liver enzymes, oral ulcers, diarrhea, mild hair loss, pneumonitis, infections, bone marrow suppression
Rheumatoid arthritis, psoriasis and psoriatic arthritis, seronegative spondyloarthropathies, arthritic/skin manifestations of systemic lupus erythematosus, granulomatosis with polyangiitis, steroid sparing agent
Cyclophosphamide Alkylating agent that inhibits cell division by cross-linking DNA and reducing DNA synthesis
Infections, bladder toxicity with hemorrhagic cystitis or carcinoma, secondary malignancy, premature ovarian failure, infertility, neutropenia, hair loss, bone marrow suppression, oral ulcers
Systemic lupus erythematosus nephritis or other life-threatening manifestations, rheumatoid arthritis transverse myelitis, systemic sclerosis-related ILD, granulomatosis with polyangiitis, polyarteritis nodosa, rheumatoid vasculitis
Inhibits inosine monophosphate dehydrogenase, affecting de novo purine synthesis in activated lymphocytes
Diarrhea, abdominal cramps, nausea, infection, bone marrow suppression, neoplasia, rash, tremor
Systemic lupus erythematosus nephritis or other serious manifestations, myasthenia gravis, systemic vasculitis
Purine antagonist, inhibits synthesis of DNA, RNA, proteins, cellular metabolism
Bone marrow suppression, infection, gastrointestinal upset, nausea, neoplasia
Maintenance therapy for systemic lupus erythematosus nephritis, treatment and/or maintenance for other manifestations of SLE, ulcerative colitis, Crohn’s disease rheumatoid arthritis, ANCA-positive vasculitis
Calcineurin inhibitors; inhibit transcription of IL-2 production, proliferation of T lymphocytes; inhibits production of IL2, IL-4, and CD40 ligand. Voclosporin is in clinical trials for lupus nephritis
Renal toxicity, hypertension, neurologic side effects, skin or lymphoproliferative disorders, significant drugdrug interactions
Refractory ocular and mucocutaneous Behc¸et’s disease, adult systemic lupus nephritis, systemic sclerosis, severe ulcerative colitis, myasthenia gravis; typically not first-line therapy
Infusion reactions to IV infliximab (but not to subcutaneous), rash, arthralgias, fatigue, infection, increased risk of lymphoma, skin cancers, neurologic disorders
Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis (inflix, etan, ada), juvenile idiopathic arthritis (etanercept and adalimumab), Crohn’s disease, and ulcerative colitis. Uveitis (adalimumab)
BIOLOGIC DMARDS Infliximab Adalimumab Golimumab Etanercept
Tumor necrosis factor inhibitor; downregulates inflammatory cytokines, inhibits immunoregulatory functions of TNF
TREATMENT OF AUTOIMMUNE DISEASE: ESTABLISHED THERAPIES
Primary mechanism of action
IL-6R antagonist leading to reduced cytokine and proinflammatory pathways
Neutropenia, thrombocytopenia, elevated liver enzymes, GI perforation, infections, hyperlipidemia, rash
Rheumatoid arthritis, giant cell arteritis, systemic and polyarticular juvenile idiopathic arthritis
Antagonists of IL-1R, therefore inhibits inflammasome
Nausea, diarrhea, vomiting, eosinophilia, leukopenia, headache, infection
Rheumatoid arthritis, neonatal onset multisystem inflammatory disease (anakinra), systemic juvenile idiopathic arthritis, acute or uncontrolled gout. Canakinumab is approved for Familial Mediterranean Fever, cryopyrin-associated periodic syndromes, and TNF receptorassociated periodic syndromes
Anti-CD20 monoclonal antibody against B cells
Infusion reaction, infections. Reduced Rheumatoid arthritis, granulomatosis with vaccination response, mucocutaneous polyangiitis, microscopic polyangiitis, reactions, malignancy, rare PML due to systemic lupus erythematosus JC virus, cytopenias
Inhibits cytokine B lymphocyte stimulator protein (BLys, also called BAFF) necessary for B-cell proliferation, survival, and differentiation
Infections. Nausea, diarrhea, fever, insomnia, depression, leukopenia, angioedema, hypersensitivity to IV infusion. Recently available in the United States in subcutaneous injectable form
Mild-to-moderate autoantibody-positive SLE (has not completed testing in lupus nephritis and has not been used in patients with active central nervous system lupus)
Inhibits IL-17A and the release of IL17-stimulated chemokines and proinflammatory cytokines
Infections. Neutropenia, nausea, diarrhea, anaphylaxis to IV doses, urticaria, can induce inflammatory bowel disease
Psoriasis, psoriatic arthritis, and ankylosing spondylitis
Inhibits IL-12 and IL-23-mediated cell signaling and cytokine production
Crohn’s disease, plaque psoriasis, and Infections. Nasopharyngitis, increased psoriatic arthritis risk of nonmelanoma skin cancers, injection site erythema, headache, reversible posterior leukoencephalopathy syndrome, arthralgia, headache, back pain, nausea, diarrhea
CTLA4Ig fusion protein: binds CD80 and 86, preventing their binding to CD28, thereby inhibiting T-cell activation
Infections. Headache, nausea, malignancy, may induce multiple sclerosis (very rare), vasculitis, nasopharyngitis, dizziness, back pain, extremity pain
Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, lupus arthritis
Inhibits PDE4, results in increased intracellular cAMP levels
Headache, depression, diarrhea, nausea, decreased appetite, infection, rash, weight loss
Psoriasis, psoriatic arthritis
Inhibits JAK enzymes, preventing cytokine signaling of immune cells
Infection. Increased liver enzymes, infection, anemia, lymphopenia, hyperlipidemia, headache
Rate-related infusion reactions, headache, aseptic meningitis, acute renal failure, thrombosis, urticaria, anaphylaxis, especially in IgA-deficient patients
GuillainBarre´ syndrome, myasthenia gravis, autoimmune peripheral neuropathies, rheumatic hematologic autoimmune thrombocytopenia, or hemolytic anemia, refractory dermatomyositis or polymyositis, Kawasaki disease in children
OTHER THERAPIES IVIG
Interference with Fc receptors, antiidiotypic antibodies, inhibition of reticuloendothelial clearance
US FDA has approved therapies for diseases listed in italics or are expected to soon do so. DMARD, Disease-modifying antirheumatic drugs; GI, gastrointestinal; ILD, interstitial lung disease; IL, Interleukin; IVIG, intravenous immuneglobulin; JC, John Cunningham virus; JAK, Janus kinase; NFκB, nuclear factor kappa B; PML, progressive multifocal leukoencephalopathy; TLR, Toll-like receptor; TNF, tumor necrosis factor.
71. TREATMENT OF AUTOIMMUNE DISEASE: ESTABLISHED THERAPIES
PRINCIPLES OF IMMUNE SUPPRESSION As with our oncology colleagues, the goals for physicians treating autoimmune diseases are to induce improvement (remission or low disease activity), while arresting irreversible organ damage and minimizing treatment side effects. Although definitive cure and restoration of permanent immunological tolerance would be ideal, most treatments now do not achieve that goal. Treatments are often nonspecifically antiinflammatory and/ or immunosuppressive. Thus the substantive side effects that accompany such treatments require balancing the risks of infection, bone marrow suppression, and other organ toxicity with potential efficacy. In recent years, the paradigm of “tight control” has emerged, in which goal-directed treatments are based on quantitative and disease-specific measurements that guide providers to rapidly achieve low disease activity or remission. Notably, “tight control” in rheumatoid arthritis (RA) was illustrated in the TICORA study (Grigor et al., 2004) in which 111 patients were randomly assigned to either an intensive or a routine management group. Intensive management consisted of monthly office visits, measurements of disease activity scores (DAS), steroid injections of swollen joints, and every 3 month escalation of treatment by a defined protocol if moderate or high disease activity persisted. In contrast, the routine management group was seen every 3 months, without DAS measurement, and steroid injections and treatment escalation were based on the clinical judgment of the clinician, in contrast to predefined formal targets. After 18 months, patients in the tight control/intensive group showed significantly improved disease activity, physical function, and quality of life, as well as less radiographic progression of arthritis—all at no additional cost compared to routinely managed patients. The BeST study (Goekoop-Ruiterman et al., 2007; Goekoop-Ruiterman et al., 2005) and others (Mottonen et al., 1999; Rantalaiho et al., 2009) similarly illustrated greater remission rates and earlier functional improvement in RA arthritis patients with early, goal-directed therapy emphasizing aggressive treatment to achieve tight control of disease. Given the clear advantages of intensive treatment, the tight control paradigm is reflected in the 2015 update of the American College of Rheumatology’s recommendations for the use of disease-modifying antirheumatic drugs (DMARD) and biologics in the treatment of RA (Singh et al., 2016). With greater integration of quantitative measurements and DAS to define targets for treatment remission, goal-directed therapy as demonstrated in RA may serve as a harbinger for tight control treatment algorithms under study in other autoimmune diseases. Already, there is interest in working groups for establishing similarly objective “tight control” measures for seronegative spondyloarthropathies, systemic lupus erythematosus (SLE), and others.
GENERAL CONSIDERATIONS For many autoimmune disorders, chronic inflammation can lead to a variety of nonspecific, constitutional symptoms that include fatigue, muscle pains, weight loss, and/or fever. In fact, 40%80% of the patients with SLE (lupus) experience such constitutional symptoms at any one time (Von Feldt, 1995). Furthermore, constitutional symptoms are present in a variety of other disorders such as multiple sclerosis, RA, multisystem autoimmune diseases, and vasculitis. General therapeutic principles focus on treating reversible causes of fatigue, weakness, and weight loss, such as anemia, drug toxicities, and ruling out other potential etiologies such as malignancy, infections, or thyroid/endocrine disorders. Proper muscle conditioning with appropriate aerobic exercise, good sleep management, and pain control may improve symptoms. Some studies have shown that stress may induce or exacerbate preexisting lupus symptoms (Blumenfield, 1978; Otto and Mackay, 1967), in which overall stress reduction may be beneficial (Greco et al., 2004). In addition, management of precipitating environmental factors such as sun exposure and tobacco smoke is important. UV light in SLE patients induces increased apoptosis in skin cells, thus enhancing self-antigenicity of keratinocytes to express self-antigens on their surface that may stimulate an inflammatory response and autoantibody production leading to photosensitivity, cutaneous SLE, and/or generalized flares (Casciola-Rosen et al., 1994; Jones, 1992). Furthermore, genetically prone RA patients that carry an epitope in the hypervariable region of the human leukocyte antigen-DR (HLA-DR) chain, known as the “shared epitope,” have a higher risk of developing RA if they smoke cigarettes (Padyukov et al., 2004). The relative risk for development of RA in current smokers is 2.35.6-fold higher than for nonsmokers. In another study, the relative risk for developing RA was 20-fold higher in those with two alleles of the shared epitope, a smoking history, and anticyclic citrullinated peptide (anti-CCP) antibodies (Klareskog et al., 2006). Smoking may also increase disease severity (Saag et al., 1997; Wolfe, 2000). The mechanism of interaction between smoking and the shared epitope may primarily affect
NONSPECIFIC ANTIINFLAMMATORY DRUGS
citrullination of proteins in inflamed synovial tissue. The association between smoking and RA was most robust in patients with anti-CCP autoantibodies detected in blood (Klareskog et al., 2006). Studies have shown an association with smoking and development of autoantibodies, such as antinuclear antibodies (ANA) (Regius et al., 1988). Smoking may also be associated with increased risk for development of SLE (Ghaussy et al., 2001) and Crohn’s disease, although it may lessen the risk of developing ulcerative colitis (UC) (Mahid et al., 2006; Tobin et al., 1987). Hence, simple but important lifestyle changes such as reducing sun exposure (for SLE) and avoiding tobacco (for RA, SLE, and Crohn’s disease) are important therapeutic considerations in management of autoimmune diseases.
NONSPECIFIC ANTIINFLAMMATORY DRUGS Nonsteroidal Antiinflammatory Drugs Nonsteroidal antiinflammatory drugs (NSAIDs) are widely used throughout the world either over the counter or via prescription. All major NSAID classes share the common mechanism of inhibiting cyclooxygenase, which metabolizes arachidonic acid to cyclic endoperoxidases to form prostaglandins. Prostaglandins’ role in inflammation includes induction of swelling, erythema, neutrophil trafficking, changes in vascular permeability, and inhibition of apoptosis (Harris, 2002; Lu et al., 1995). In addition, other nonprostaglandin mechanisms include NSAID inhibition of nuclear factor kappa B (NFκB)dependent transcription (Amin et al., 1995), thus decreasing nitric oxide that normally may lead to increased vascular permeability and immune cell trafficking. NSAIDs are used commonly in multisystem autoimmune diseases to treat constitutional symptoms, fever, arthritis, serositis, and headache. The potential adverse effects (AEs) of NSAIDs often limit their use, particularly induction of dyspepsia, peptic ulcer disease (often with bleeding), renal vasoconstriction with acute renal injury, and exacerbation of hypertension and heart failure (Solomon, 2012), with increased risk for myocardial infarction. Thus, for safety concerns, they are recommended most commonly for as-needed (for pain and/or joint inflammation) rather than continual use. According to Epocrates searched on March 2018, a monthly dose of ibuprofen (400 mg tid) costs $24.00.
Glucocorticoids GCs have a broad range of antiinflammatory and immunosuppressive effects on both the innate and adaptive immune system. GC binds to an intracellular receptor, where they can directly affect gene transcription, resulting in inhibition of production of inflammatory cytokines, and effects on posttranslational mRNA stability. Antiinflammatory effects include downregulation of nitric oxide synthesis resulting in reduced blood vessel permeability, decreased leukocyte migration to peripheral tissues, inhibition of inflammatory mediators such as eicosanoids, inhibition of collagenases, and suppression of inflammatory cytokines. Effects of GC on immune cells include inhibition of signaling for T-cell activation and interleukin (IL)-2 synthesis, downregulation of APCs via blockade of costimulatory molecules, immune deviation toward Th2 cytokines, and induction of T-cell apoptosis (Kirouka, 2007). GCs are often used to control acute manifestations of inflammatory and autoimmune disorders, dosed on a mg/kg basis depending on the severity of the disease. Typical dosing regimens may be divided as follows from most potent to least: (1) pulse intravenous (IV) therapy with methylprednisolone 5001000 mg/day, (2) very high-dose oral GC at 12 mg/kg/day prednisone or equivalent, (3) high-dose oral GC at 0.61 mg/kg/day prednisone or equivalent, (4) medium-dose GC at 0.1250.5 mg/kg/day prednisone or equivalent, or (5) low-dose GC at 0.125 mg/kg/day prednisone or equivalent (King and Hahn, 2007). Organ threatening manifestations of disease in SLE, dermatomyositis, large and small vessel vasculitis, and multiple sclerosis often require pulse IV steroids as part of the initial induction therapy for acute flare control. Other common indications include polymyalgia rheumatica, crystalline disease flares, active RA, and Sjo¨gren’s extrasalivary gland manifestations. GCs have numerous AEs on many organ systems, more common with use of GC in high doses or over a long period of time. Major AEs with high dose (prednisone .20 mg/day) include infection, mental disturbances, osteonecrosis, osteoporosis with fractures, and impact on safety with live vaccination. For use of prednisone doses .10 mg/day, there is increased risk of glucose intolerance, peptic ulcer disease, myopathy, glaucoma, and hypertension. Weight gain is found as a common side effect even with the low dose, prednisone .5 mg/day and osteoporosis risk with the doses $ 57.5 mg/day for 3 months (Saag et al., 2011). Recent data (Al Sawah et al., 2015) show that doses of prednisone $ 7.5 mg of prednisone daily are associated with measurable damage over
71. TREATMENT OF AUTOIMMUNE DISEASE: ESTABLISHED THERAPIES
time, but doses .20 mg a day cause damage at twice that rate. Most authorities recommend tapering to doses between 0 and 7.5 mg a day for this reason. According to Epocrates in March 2018, a monthly dose of prednisone 15 mg daily costs $48.00.
ESTABLISHED TREATMENTS OF RHEUMATIC DISEASES Antimalarials Antimalarial medications such as hydroxychloroquine, chloroquine, and quinacrine can be used to treat mild-to-moderate manifestations of SLE or RA and other rheumatic disorders. Various mechanisms of action may contribute to their utility in immune modulation, including (1) inhibition of activation of intracellular Tolllike receptor (TLR)-3 and TLR-7, (2) blockade of antigen processing by raising intracytoplasmic pH in lysozymes with resultant decreased lymphocyte proliferation, autoantibody production, and natural killer cells (NK) activity, and (3) inhibition of formation of immune complexes (Fox, 1993; Fox and Kang, 1993; Kyburz et al., 2006). In addition, antiinflammatory effects include inhibition of phospholipases, prostaglandins, blockade of superoxide secretion, suppression of destructive proteolytic enzymes by synoviocytes, and blockade of UV light to protect keratinocytes from increased antigenicity (Wallace, 2007). Hormonal actions may impair insulin release, antiproliferative effects may inhibit graft versus host disease, and intercalation with DNA may block synthesis to allow degradation of ribosomal RNA (Wallace, 2007). Hydroxychloroquine and chloroquine can also inhibit platelet aggregation and adhesion (Edwards et al., 1997; Ernst et al., 1984; Jancinova et al., 1994), adding to their utility for SLE patients with coexisting antiphospholipid syndrome and/or platelet abnormalities. In SLE, antimalarials are most useful in treating constitutional symptoms, skin lesions, and arthritis, and for reduction of disease flare. In addition, the 2007 LUMINA trial illustrated an association between hydroxychloroquine and improved survival (Alarcon et al., 2007). Pregnant mothers with anti-Ro may use hydroxychloroquine to reduce risk of antibody-associated cardiac neonatal lupus (Izmirly et al., 2010). In RA, antimalarials are typically used in combination with other disease-modifying agents, such as methotrexate (MTX) or sulfasalazine. A large observational study indicated reduced risk of diabetes mellitus among patients who were taking hydroxychloroquine for RA compared to those not taking the medication (Wasko et al., 2007). Antimalarials may also decrease antibody levels in Sjo€gren’s syndrome, as well as improve sicca symptoms by inhibiting glandular cholinesterase (Dawson et al., 2005). Hydroxychloroquine has also been used in systemic onset juvenile idiopathic arthritis (Still’s disease), juvenile dermatomyositis, and palindromic rheumatism. One study found that the use of antimalarials in palindromic rheumatism patients was associated with a 20% decreased risk of progression to RA or other connective tissue disease (Gonzalez-Lopez et al., 2000). Side effects vary with specific antimalarials (in general the highest risk of important AEs is associated with chloroquine). These side effects include neuromuscular and cardiac toxicity, skin changes (particularly hyperpigmentation with all, and yellow discoloration with quinacrine), aplastic anemia (quinacrine), and rare ocular effects, including macular damage. Regular ocular screening of patients treated for more than 6 months with chloroquine or hydroxychloroquine is recommended (Marmor et al., 2011). For maximal safety regarding retinal toxicity, doses of hydroxychloroquine should not exceed 5 mg/kg daily (real weight); and risk for retinal toxicity increases after a total cumulative dose of 1000 g. According to Epocrates searched on March 2018, a monthly dose of hydroxychloroquine (400 mg daily) costs $240.00.
Sulfasalazine Sulfasalazine (azulfidine) was originally proposed for use in RA, although ultimately great benefit was seen in treatment for inflammatory bowel disease (IBD). After oral ingestion, the majority of the intact drug reaches the large intestine and is reduced to sulfapyridine and 5-aminosalicylic acid (5-ASA). For IBD, and specifically UC, 5-ASA acts locally in the colon to decrease inflammatory responses via inhibition of prostaglandin synthesis. Interestingly, in contrast to UC, the active metabolite in RA patients is sulfapyridine, although the exact mechanism of action has not been clearly identified. Patients with mild/moderate UC treated with azulfidine or 5-ASA have 50%65% response rates (MacDermott, 2017). Patients with RA show approximately 50% response rates (20% improvement or better) to sulfasalazine alone, and better response rates (nearly 80%) for triple therapy with sulfasalazine plus MTX plus hydroxychloroquine (Weisman and Rinaldi, 2017). In addition, studies suggest that the parent sulfasalazine drug inhibits NFκB transcription, may inhibit tumor necrosis factor (TNF)-α in
ESTABLISHED TREATMENTS OF RHEUMATIC DISEASES
macrophages by inducing apoptosis, and may suppress B-cell function (Hirohata et al., 2002; Lee et al., 2004; Rodenburg et al., 2000; Wahl et al., 1998). In RA, sulfasalazine is often used in combination therapy with other DMARDs for optimal treatment. AEs include elevated liver function tests, leukopenia, agranulocytosis, megaloblastic anemia, and gastrointestinal or central nervous system effects. In men, transient infertility has been observed with qualitative and quantitative abnormalities in sperm including oligospermia and sperm dysmotility. These effects were reversible 13 months after discontinuation of sulfasalazine (Ostensen, 2017; Sands et al., 2015). According to Epocrates searched on March 2018, the monthly cost of sulfasalazine at 1 g bid is $41.00. The monthly cost of triple therapy with sulfasalazine plus MTX at 15 mg a week orally plus hydroxychloroquine at 400 mg daily is approximately $300.00, which is considerably less expensive than the widely used MTX-plusadalimumab (biologic inhibitor of TNF-α which is given 40 mg subcutaneously every 2 weeks which costs approximately $5000 per month), a combination which costs approximately $5125.00 per month.
Leflunomide Leflunomide (LF) is an oral medication that, once absorbed, is metabolized into its active form known as teriflunomide. The main mechanism of action of teriflunomide is to inhibit the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH), which is an enzyme involved in the de novo pyrimidine synthesis pathway of ribonucleotide uridine monophosphate pyrimidine. Disruption of DHODH prevents activated lymphocytes from moving from the G1 to S phase (Fox, 1998). In addition, the immunomodulatory effects of LF are broad, including inhibition of leukocyte adhesion to endothelial cells and infiltration into synovium, which may be of particular importance in RA (Dimitrijevic and Bartlett, 1996; Grisar et al., 2004; Salmi et al., 1997). In addition, LF preferentially inhibits memory self-reactive lymphocytes, affects dendritic cell antigen presentation, and blocks NFκB activation (Manna and Aggarwal, 1999; Zhang et al., 1997). LF blocks protein tyrosine kinases Jak1 and Jak3, which affect T-cell stimulation via IL-2 receptor activation (Siemasko et al., 1998). LF may also increase the production of transforming growth factor beta, which is a known antiinflammatory cytokine (Cao et al., 1996). In patients with RA, LF is similar in efficacy to MTX; each treatment used alone results in 20% or greater improvement in approximately 50% of the patients. Common side effects include diarrhea, rash, hair loss, and elevated liver enzymes. Less common side effects include hypertension, interstitial pneumonitis, leukopenia, hematologic toxicities, and peripheral neuropathy. LF is contraindicated in pregnant and nursing women and in patients with preexisting liver disease. LF is approved by the United States Food and Drug Administration (US FDA) for the treatment of RA. In RA, trials have demonstrated efficacy of LF as monotherapy, with comparable outcomes to those of MTX or sulfasalazine monotherapy (Emery et al., 2000; Smolen et al., 1999). Other trials have shown efficacy in psoriatic arthritis (PsA), juvenile polyarthritis, and resistant dermatomyositis, but not ankylosing spondylitis (AS). In www.goodrx.com searched on March 2018, a month supply of LF at a dose of 20 mg daily orally costs $200400.
Methotrexate MTX is a folate antagonist that has been used effectively in a variety of autoimmune conditions. Competitive binding blocks the enzyme dihydrofolate reductase from reducing dihydrofolic acid to folinic acid, the active intracellular metabolite involved in purine/pyrimidine metabolism, and amino acid/polyamine synthesis. However, at the doses used in rheumatic conditions, which are often lower than in oncologic chemotherapeutic regimens, the exact mechanism of action is uncertain. Animal models suggest that MTX increases extracellular concentrations of adenosine in inflammatory tissue, which has antiinflammatory effects via dephosphorylation of adenine nucleotides (Cronstein, 1996; Morabito et al., 1998). Other possible mechanisms include inhibition of DNA methylation necessary for cell proliferation, induction of apoptosis of activated peripheral T cells, regulation of IL-1β, increased IL-10 synthesis, inhibition of leukotriene B2 formation and cyclooxygenase-2, and interference with neutrophil function (Cronstein, 1996; Genestier et al., 1998; Mello et al., 2000; Seitz et al., 2001). MTX can be taken orally, subcutaneously, or intramuscularly. In RA, approximately 50% of the patients with RA show 20% or better improvement in joint scores. Side effects include elevation of liver enzymes, especially when concurrently ingesting alcohol, oral ulcers, postingestion nausea, diarrhea, and hair loss. More severe complications include pneumonitis, infections due to immune suppression, bone marrow suppression, and hepatic fibrosis. Folic or folinic acid is often used as supplementation to reduce hematologic and other side effects, although folinic acid may interfere with efficacy. Pregnancy should be avoided, as MTX is a known teratogen.
71. TREATMENT OF AUTOIMMUNE DISEASE: ESTABLISHED THERAPIES
MTX is used in a variety of rheumatic conditions, most prominently in RA, but also in psoriasis/PsA, peripheral joint disease in spondyloarthropathies, SLE, granulomatosis with polyangiitis (GPA) (formerly called Wegener’s granulomatosis), and other large vessel vasculitides. Barring contraindications or allergy, MTX can be considered one of the cornerstones of DMARDs for the treatment of RA. Studies have shown both short-term and long-term efficacy in RA disease measurements, such as joint pain and swelling, quality of life, objective laboratory markers of inflammation, and radiologic progression of disease (Rich et al., 1999; Weinblatt et al., 1992, 1994), as well as possible improvement in survival (Choi et al., 2002). MTX monotherapy is first-line treatment for RA. If there is not adequate improvement in disease activity after several weeks, it is used in combination therapy with other DMARDs, such as sulfasalazine or hydroxychloroquine, or biologics (O’Dell et al., 1996; Weinblatt, 2013). Numerous trials have demonstrated the value of MTX in combination therapy on disease activity measures, reduction of radiographic progression, and functionality. MTX is often used in other disorders to treat peripheral joint arthritis symptoms, such as in psoriasis (35%40% have 75% or greater clearing of skin lesions), seronegative spondylarthritis disorders, and joint manifestations in lupus patients. In vasculitides such as GPA, oral MTX can be used as initial therapy for nonorgan threatening, nonrenal disease, although its use is associated with a higher relapse rate compared to cyclophosphamide (CYC). Thus MTX is a reasonable alternative for patients who cannot tolerate other more toxic (but more effective) treatment regimens (De Groot et al., 2005; Mukhtyar et al., 2009). In addition, MTX may be used as a steroid-sparing agent in the large vessel vasculitis in giant cell arteritis, although there is conflicting evidence of its efficacy in this setting (Hoffman et al., 2002; Jover et al., 2001). According to Epocrates searched on March 2018, the monthly cost of 15 mg daily of MTX once a week orally is approximately $22.00.
Cyclophosphamide CYC is a potent alkylating agent, used most often to treat life-threatening or organ-threatening manifestations of autoimmune and inflammatory diseases. It can be administered orally or intravenously and is metabolized by the liver mitochondrial P-450 enzyme into several active metabolites with both therapeutic and toxic effects. CYC has direct effects on DNA resulting in cell death and modulates T-cell activation (Fox and McCune, 1994; McCune and Fox, 1989). Significant side effects often limit more widespread use and include an increased risk for opportunistic infections such as Pneumocystis jiroveci pneumonia and fungal infections, bladder toxicity with hemorrhagic cystitis and carcinoma of the bladder, neutropenia, increased risk of infertility or premature ovarian failure, and development of malignancy. Short-term therapeutic use of CYC aims for rapid control of the underlying inflammatory process (over a period of a few weeks to months), while seeking replacement of CYC when possible with an acceptable alternative to avoid the significant long-term toxicities. CYC has been used effectively in the treatment of lupus nephritis, interstitial lung disease in multisystem autoimmune disease, and medium and small vessel vasculitis. In patients with severe lupus nephritis, initial landmark trials from the National Institute of Health demonstrated the superiority of monthly high-dose IV CYC (5001000 mg/m2) for 6 months, followed by two quarterly pulses with GCs, versus GC therapy alone in preserving renal function (Austin et al., 1986; Boumpas et al., 1992; Gourley et al., 1996; Illei et al., 2001). Subsequent studies have investigated the role of low-dose CYC regimens (500 mg IV every 2 weeks for 36 months) and found that this regimen compared to the higher dose CYC produces similar rates of renal remission in European patients—for up to 10 years (Houssiau et al., 2010b, 2002). It is not known whether the low-dose regimen is effective in African Americans, Asians, or Latinos with lupus nephritis. Small studies suggest a role for CYC in treatment of central nervous system manifestations of SLE, such as transverse myelitis (Barile and Lavalle, 1992; Kovacs et al., 2000; Neuwelt et al., 1995). CYC has also demonstrated improvement in pulmonary function, dyspnea, skin thickening, and health-related quality of life in patients with symptomatic systemic sclerosisrelated interstitial lung disease (Tashkin et al., 2006). CYC is a second-line agent alternative to mycophenolate for most cases of systemic sclerosis-related interstitial lung disease due to its AEs (Tashkin et al., 2016). Systemic vasculitides such as GPA, microscopic polyangiitis, anti-neutrophilic-cytoplasm antibody (ANCA)-positive vasculitis, rheumatoid vasculitis, polyarteritis nodosa, autoimmune-associated mononeuritis multiplex, and optic neuritis are other indications for CYC in which significant clinical improvement and/or survival benefits have been shown (Galindo-Rodriguez et al., 1999; Ribi et al., 2010; Scott and Bacon, 1984; Stone, 2010). CYC may be administered IV at 34 week intervals (or longer) or orally on a daily basis: the incidence of urinary bladder toxicity is probably higher with daily oral dosing. Medicare reimbursement for a 1 g/kg dose of CYC IV is approximately $1200.00 (Afifi et al., 2016).
ESTABLISHED TREATMENTS OF RHEUMATIC DISEASES
Mycophenolate Mofetil (Cellcept) Mycophenolate mofetil (MMF) was used initially in the 1990s for the prevention of allograft rejection in renal transplantation. In the past decade, MMF has been shown to be an effective therapy in both induction and maintenance of improvement in SLE nephritis, thus allowing for use of an alternative regimen to CYC. MMF reversibly inhibits the enzyme inosine monophosphate dehydrogenase, which is necessary for de novo purine synthesis in activated lymphocytes. Blockade with MMF results in reduced T- and B-cell proliferation, less antibody production, induction of apoptosis of activated T lymphocytes, and hindrance of production and function of adhesion molecules important for lymphocyte migration to inflammatory tissues (Allison and Eugui, 2000). Side effects include diarrhea, nausea, gastrointestinal upset, infections, bone marrow toxicity, neoplasia, and rash. MMF compared to CYC is less likely to cause alopecia and amenorrhea, but rates of infection, serious infection, and death are similar with the two treatments (Touma et al., 2011). MMF is teratogenic and should be stopped if pregnancy is being considered. The use of MMF has profoundly changed the outcomes and therapeutic landscape in induction therapy of improvement in diffuse proliferative and membranous serious SLE-related glomerulonephritis. Initial studies in Chinese patients suggested that MMF was an effective alternative to CYC (Chan et al., 2000; Hu et al., 2002). Subsequent clinical trials compared CYC to MMF. A recent international, randomized controlled trial (ALMS trial) of 370 SLE patients with active nephritis compared MMF (23 g/day) to IV CYC (0.51 g/m2) monthly for 6 months. This induction therapy showed similar efficacy between the two treatments (Appel et al., 2009). Interestingly, however, proportions of African-Americans and Latino Americans responding to CYC were lower compared to Caucasians and Asians, whereas responses in all four racial groups to MMF were similar (Isenberg et al., 2010). A subsequent metaanalysis confirmed MMF and CYC to be equivalent in efficacy and side-effect profiles (Touma et al., 2011), although MMF was not superior to CYC as suggested by an earlier randomized but not blinded clinical trial (Ginzler et al., 2005). A follow-up analysis from the ALMS trial examining nonrenal lupus activity in the same nephritis patients showed similar efficacy between MMF and CYC on nonrenal manifestations, thus suggesting MMF as a reasonable alternative to CYC for renal and nonrenal SLE (Ginzler et al., 2010). Furthermore, in addition to the above trials demonstrating MMF’s utility in induction therapy in SLE, a recent study has demonstrated MMF’s superiority in safety and efficacy as maintenance therapy for SLE nephritis compared to CYC (Contreras et al., 2004) and azathioprine (AZA) (Dooley et al., 2011; Houssiau, 2016). The American College of Rheumatology’s 2012 guidelines for treatment and management of classes III, IV, and V glomerulonephritis reflect the current state of the art regarding use of MMF (Hahn et al., 2012). It is a first choice for induction therapy (with GCs) and maintenance therapy in lupus nephritis patients who are not Caucasian or Asian, since similar proportions respond in all racial groups. Short-term therapy (6 months) with IV CYC can be chosen instead; higher proportions of Caucasians and Asians respond compared to Blacks and Latinas, but there are good responders in all groups. MMF has been successfully used for treating systemic sclerosis, myositis, uveitis, and vasculitis (GPA maintenance therapy). Because of its antilymphocyte and antifibrotic effects, it has been effective in treating interstitial lung disease associated with many rheumatic diseases (Fischer et al., 2013; Morganroth et al., 2010). MMF has also been used as a steroid-sparing agent for the treatment of other rheumatic diseases and for the treatment of autoimmune hepatitis. MMF is approved by the FDA in adults and children for maintenance of renal, liver, and heart transplants. An induction dose of MMF, 3 g orally daily, costs approximately $1300 per month according to Epocrates, searched on March 2018.
Azathioprine (Imuran) AZA is a prodrug that is metabolized to its active component 6-mercaptopurine (6-MP), a purine antagonist that inhibits DNA synthesis that leads to both cytotoxicity and decreased cellular proliferation. Intracellular metabolism of 6-MP results in decreased numbers of circulating lymphocytes, IL-2 secretion, and immunoglobulin production (Wilke, 2010). It is approved by the US FDA for prevention of renal transplant rejection and the treatment of RA; however, off-label use is common for remission maintenance of many rheumatic diseases such as SLE, polymyositis/dermatomyositis, Behc¸et’s disease, ANCA-associated vasculitis, or as a steroid-sparing agent in many other rheumatic diseases. AEs include nausea, vomiting, bone marrow suppression (particularly anemia), increased risk of infection, and malignancy. Individuals with a homozygous genetic polymorphism of the enzyme thiopurine methyltransferase that reduces the metabolism of AZA may be at greater risk for AZA bone marrow toxicity. Some authorities recommend checking for this genetic polymorphism prior to initiation of therapy. A number of studies have shown efficacy of AZA over placebo in the
71. TREATMENT OF AUTOIMMUNE DISEASE: ESTABLISHED THERAPIES
treatment of RA (Cade et al., 1976; Urowitz et al., 1973; Woodland et al., 1981), although more recent combination therapies of MTX plus biologics or other DMARDs are better. Recent data in RA suggested combined MTX and AZA had statistically more withdrawals due to adverse events than oral MTX alone (Hazlewood et al., 2016). In addition, AZA can be used for effective maintenance therapy in lupus nephritis (Contreras et al., 2004; Houssiau et al., 2010a), UC and Crohn’s bowel disease (Prefontaine et al., 2009; Timmer et al., 2007), ANCA-positive vasculitis (Pagnoux et al., 2008), and autoimmune hepatitis. According to Epocrates, searched on March 2018, a dose of 150 mg daily of AZA costs approximately $110.00 a month.
Calcineurin Inhibitors: Cyclosporin A, Tacrolimus, and Voclosporin Cyclosporin A (CSA) is a cyclic peptide of 11 amino acids that binds with high affinity to cyclophilins, which competitively bind to calcineurin. This leads to inhibition of translocation of transcription factors, NF-AT, thus reducing transcription of early cytokine genes that encode IL-2, TNF-α, interferon (IFN)-γ, IL-3, IL-4, CD40, and granulocyte-macrophage colony-stimulating factor (Schreiber and Crabtree, 1992; Timmerman et al., 1996; Wiederrecht et al., 1993). Furthermore, CSA interferes with antigen presentation by APCs. The ultimate net effect is reduction of lymphocyte proliferation. CSA is metabolized by the cytochrome P450 3A4 liver enzymes and has a variety of drugdrug interactions that may interfere with blood concentration levels, thus requiring monitoring of CSA levels. Side effects include renal toxicity, hypertension, neurologic side effects such as tremor, encephalopathy, increased risk of skin or lymphoproliferative malignancies, and heightened risk for infection. However, unlike many alkylating agents and purine antagonists, CSA lacks clinically significant bone marrow suppression. CSA has been used in a variety of established and suspected autoimmune disorders, including RA, PsA, ocular and mucocutaneous Behcet’s disease, adult lupus membranous nephritis, systemic sclerosis, atopic dermatitis, severe UC, pemphigus vulgaris, and myasthenia gravis (Magee, 2012). However, concern over long-term side effects, especially of renal toxicity, hypertension, and a myriad of drug interactions, has limited utility in chronic autoimmune diseases, except in patients who have failed more conventional therapies. Tacrolimus, another oral medication that inhibits T lymphocyte activation similarly to cyclosporine, is used widely for prevention of allograft rejection, because its potential AEs are slightly less than those of cyclosporine, with fewer hypertensive effects. Further, in vivo, the immunosuppressive effects are 1020 times greater than cyclosporine. It is being used for some autoimmune diseases, including induction and maintenance therapy for lupus nephritis, RA, and autoimmune hepatitis (Lee et al., 2011; Li et al., 2012). In Chinese and Japanese studies, tacrolimus was equivalent to high-dose IV CYC in lupus nephritis (Wang et al., 2012) and in combination with low-dose mycophenolate was very effective in inducing partial or complete remissions (in 83% compared to 63% on IV CYC) (Liu et al., 2015). A dose of 5 mg daily costs approximately $3000 per month according to Epocrates, searched on March 2018. Voclosporin, another calcineurin inhibitor, is part of the next generation of treatments in this class of drugs. Previously known by other names, including ISA247, its structure is the same as cyclosporine except at the amino acid-1 residue. This difference allows for higher binding to calcineurin, and higher potency compared to cyclosporine (Papp et al., 2008). The AEs are similar to other calcineurin inhibitors, including headache, hypertension, diarrhea, and respiratory infections. Voclosporin has been used as therapy in plaque psoriasis, noninfectious uveitis, and renal allograft rejection (Schultz, 2013). There are ongoing studies for its use in lupus nephritis.
BIOLOGIC AGENTS With increasing understanding of the pathogenesis of autoimmune rheumatic diseases, several biologic agents have been developed. They can be classified based on their mechanism of actions, cytokine-targeted therapies, B-cell-targeted therapies, and T-cell-targeted therapies.
Cytokine-Targeted Therapies Therapies interfering with TNF, IL 1, IL6, IL 12, IL 23 are currently available for rheumatic diseases particularly for RA, AS, juvenile chronic arthritis, psoriasis, and PsA.
Tumor Necrosis Factor Inhibitors TNF inhibitors are a class of biologic drugs utilizing monoclonal antibodies (mABs) or TNF-binding fusion proteins to neutralize and block various proteins in autoimmune disease processes. The target protein of these therapeutic mAbs is TNF-α, a pleiotropic cytokine with proinflammatory and immunoregulatory functions. TNFα interacts with two receptors, either p55 (TNF receptor 1) or p75 (TNF receptor 2), resulting in various downstream signaling pathways as part of this inflammatory process (Taylor, 2010). TNF inhibitors have a structure based on the immunoglobulin molecule, including two identical heavy chains and two identical light chains. There are two functional regions in each antibody: the variable region (Fab) and the constant region (Fc). Interaction of the Fc receptors with the Fc portion of the mAb results in blocking the interaction between TNF-α and its receptors as the therapeutic target of this class of molecules. Currently, there are five FDA-approved TNF inhibitors in the United States. Infliximab is a chimeric IgG1 mAb made of a murine Fab region linked to a human IgG1 kappa constant region. Adalimumab is a fully human recombinant Fab with a human IgG1 kappa constant region. Golimumab also is fully humanized with a human IgG1 kappa constant region. Etanercept is a recombinant fusion protein consisting of the TNF receptor 2 and the Fc fraction of a human IgG1 constant region. Certolizumab is a humanized IgG4 Fab fragment linked to polyethylene glycol. They are administered intravenously or subcutaneously. TNF inhibitors are indicated for autoimmune disease including RA, PsA, AS, plaque psoriasis, juvenile idiopathic arthritis, Crohn’s disease, and UC (Willrich et al., 2015). In RA, the TNFi usually used with MTX results in at least 20% improvement in 60%70% of the patients, 50% improvement in 40%50%, and 70% improvement in 20%30%. Placebos result in improvement rates of 1%12%. In RA, TNFi are better than MTX alone; most TNFi work better when combined with MTX. In patients with early disease (less than 3 years), remissions (defined as very low disease activity using international standard measures) occur in as many as 50% with etanercept plus MTX. They also reduce the damage that RA causes in joints (erosions and cartilage loss) (Schur, 2017). For treatment of psoriasis, the mAb anti-TNFs are more effective than the fusion protein (etanercept). The most common AEs of TNFi include acute and delayed infusion/injection reactions such as rash, arthralgias, fatigue, and myalgias. Infection with bacteria, fungus, and viruses also occurs due to blockage of the immune response, with a notable increased incidence in mycobacterial tuberculosis infections. In fact, the physician must rule out active tuberculosis before administering any of the TNF inhibitors. Other less common AEs include an increased risk of malignancy and neurological disorders. TNF inhibitors should be avoided in patients with known demyelinating disease. The monthly costs of TNFi are high. According to www.goodrx.com searched on March 2018, approximate monthly cost of etanercept usual dose of 50 mg a week subcutaneous (autoinjector) is $5400, adalimumab 40 mg every 2 weeks sc is $5000, remicaid IV at 10 mg/kg (given at 68 week intervals) is $6000, and certolizumab (preferred for patients during pregnancy) is $4000.
Tocilizumab (Anti-IL6R: Actemra) Tocilizumab is a humanized anti-IL-6 receptor mAB targeting the IL-6 pathway. IL-6, a pleiotropic cytokine, is important in the pathogenesis of RA, and other autoimmune diseases. There are two different IL-6-mediated signaling pathways (Calabrese and Rose-John, 2014). In classical signaling, IL-6 binds to the membrane bound receptor (mIL-6R) via the signal transduction protein gp130, leading to dimerization and further intracellular signaling. The second pathway relies on the proteolytic cleavage of mIL-6R, leading to the generation of soluble receptor for IL-6 (sIL-6R). Tocilizumab competitively inhibits IL-6 binding to mIL-6R and sIL-6R thereby blunting downstream proinflammatory effects. A recent clinical trial in giant cell arteritis showed tocilizumab treatment induced improvement in 56% compared to 14% on placebo, at both 6 and 12 months of treatment (Stone et al., 2017). In patients with RA, tocilizumab used in combination with MTX has been studied in randomized controlled trials compared to placebo. Findings showed the efficacy of tocilizumab in combination with MTX compared to placebo, as remission of disease based on 20%, 50%, and 70% improvement was 2.5, 3.2, and 6 times higher, respectively, in this group (Singh et al., 2011). In patients with RA, tocilizumab as monotherapy was studied in a randomized clinical trial compared to MTX, yielding 69% with 20% improvement, 44% with 50% improvement, and 28% with 70% improvement (Jones et al., 2010a). The AEs most commonly reported have been infections including pneumonia, cellulitis, herpes zoster, gastroenteritis, and diverticulitis. Other side effects include an elevation in lipid levels and cytopenias. Effective blockade of IL-6R can also decrease hepcidin levels and result in an elevation in hemoglobin production (Navarro-Millan et al., 2012). In addition to use in RA, tocilizumab has been recently approved by the US FDA for giant cell arteritis. It may also be used in other forms of
71. TREATMENT OF AUTOIMMUNE DISEASE: ESTABLISHED THERAPIES
vasculitis, and in systemic and polyarticular juvenile idiopathic arthritis. Dosed at 162 mg subcutaneously every 2 weeks (prefilled syringe), the price of a 1 month supply is approximately $2200 according to www.goodrx.com searched on March 2018.
IL-1 Antagonists IL-1 is one of the proinflammatory cytokines underlying the inflammatory symptoms of RA, systemic juvenile inflammatory arthritis (JIA), and autoinflammatory diseases. Anakinra (Kineret), rilonacept (Arcalyst), and canakinumab (Ilaris) are currently available IL-1 antagonists. Anakinra is a recombinant human IL-1 receptor antagonist; it blocks IL-1 activity by competitively inhibiting IL-1 binding to the IL-1 receptor (IL-1R). Blocking IL1 also serves to inhibit clinical response to inflammasome activation; thus these agents can be useful in inflammasomemediated conditions such as acute gout. Rilonacept is dimeric fusion protein that incorporates in extracellular domains of both IL-1R and IL-1 R accessory protein fused to the Fc portion of an IgG molecule. Canakinumab is a human mAB that targets IL-1 β. All these agents are administered by subcutaneous injection. Anakinra is effective in systemic JIAs (Nigrovic et al., 2011; Vastert et al., 2014). Anakinra can be used in combination with MTX. However, it is less effective than other biologic DMARDs in adult RA (Singh et al., 2009). Increasing data suggest that IL-1 inhibition is an effective alternative for patients with familial Mediterranean fever who do not respond to or cannot tolerate colchicine (Gul et al., 2015; Hashkes et al., 2012; van der Hilst et al., 2016). The choice of IL-1 inhibitor depends upon a combination of factors including regulatory or insurance requirements, route of administration, and cost. Canakinumab may be preferred due to its efficacy and convenience since it is given every 48 weeks. Beneficial effects of IL-1 inhibition were seen in patients with acute gout in open-label pilot studies using anakinra, 100 mg daily given subcutaneously until symptoms of acute gouty arthritis improved (So et al., 2007). Rilonacept and canakinumab are approved by the US FDA for the treatment of cryopyrin-associated periodic syndromes or catastrophic antiphospolipid syndrome (CAPS). Anakinra was also used off-label with success in CAPS. AEs include anaphylaxis/hypersensitivity reactions, infections, injection site reaction, and neutropenia. Canakinumab can also cause nasopharyngitis, headache, vertigo, and diarrhea. The monthly cost of Anakinra dosed at 100 mg subcutaneously daily is $4156 according to www.goodrx.com searched on March 2018.
Secukinumab (Anti-IL17A: Cosentyx) Secukinumab is a fully humanized (IgG1κ) mAB directed against IL-17A. IL-17A is a cytokine and the primary effector of Th-17 cells as part of the pathogenesis of several autoimmune diseases including psoriasis, PsA, and AS. More specifically, IL-17A has several functions in these diseases such as keratinocyte trafficking, acting on chemokines such as CCL20 and CXCLs (Maldonado-Ficco et al., 2016). Selective blocking of IL-17A by secukinumab has demonstrated efficacy in these autoimmune diseases. For example, secukinumab in patients with moderate-tosevere plaque psoriasis induced 75% or greater improvement in the surface area of plaques in almost 80% of the individuals, compared to 44% with etanercept and 5% on placebo (using the psoriasis activity scoring index (PASI) score, a standard measurement of extent of psoriasis). The efficacy of secukinumab (and other IL17 inhibitors that are currently available) in plaque psoriasis is probably the best to date among the biologics (Feldman, 2017). Secukinumab showed significant but not dramatic response in patients with PsA in previous clinical trials with 20% improvement noted in 54% and 51% of the 300 and 150 mg dosed groups, respectively, as compared to placebo (McInnes et al., 2015). AEs of secukinumab include neutropenia, and infections notable for candidiasis (Baeten et al., 2015). According to www.goodrx.com (searched on April 2018), a monthly dose of secukinumab at 150 mg subcutaneously weekly costs $4700. However, the biologic can be withheld for a few weeks after the first 5 weeks if there is good response, so the high monthly cost may be intermittent.
Ustekinumab (Anti-p40 for IL-12 and IL-23 Signaling: Stelara) Ustekinumab binds to the p40 subunit of IL-12 and IL-23. This then prevents binding to the IL-12 and IL-23 receptors, inhibiting IL-12 and IL-23-mediated cell signaling, activation, and cytokine production, including Th1 and Th17 production of IFN-γ, IL-17, and IL-22 (Yeilding et al., 2012). In patients with active PsA, multicenter placebo-controlled trials showed significant improvement compared to placebo at doses of 45 and 90 mg with 42% and 49%, respectively, achieving 20% improvement, compared to 22% on placebo with 20% improvement
(McInnes et al., 2013). In psoriasis, ustekinumab treatment of moderate-to-severe plaque disease results in 67% of the patients achieving 75% or greater reduction of total skin involved (PASI score) (Feldman, 2017). AEs include infections, such as nasopharyngitis. There is also increased risk of nonmelanoma skin cancers as demonstrated in postmarketing data (Baker and Isaacs, 2017). Ustekinumab has been FDA-approved for use in Crohn’s disease, plaque psoriasis, and PsA. A single injection of ustekinumab subcutaneous is approximately $10,600, but it is given once every 12 weeks for psoriasis and PsA, making the monthly cost $3533 (www.goodrx.com searched on April 2018).
B-Cell-Targeted Therapies Targeting autoreactive B cells or B-cell maturation signals has become successful therapy for autoimmune rheumatic conditions and will be discussed briefly here and in further detail in the next chapter.
Rituximab (Rituxan) Rituximab is a chimeric anti-CD20 mAB, which causes depletion of B cells via various mechanisms, including Fc gamma receptor-mediated antibody-dependent cytotoxicity, antibody-dependent complement-mediated cell lysis, and B-cell apoptosis (Cragg et al., 2005). Rituximab selectively depletes CD20 1 B cells, which play a role in autoantibody-mediated diseases including the chronic synovitis associated with RA (Tsokos, 2004). Results of the RAVE and RITUXVAS trials in patients with ANCA vasculitis show that rituximab is an effective and safer alternative to CYC, especially in patients with relapsing disease (Jones et al., 2010b; Stone et al., 2010). Of note, in prospective, controlled randomized trials, rituximab was not shown to be superior to placebo for treatment of SLE patients with active disease (renal or nonrenal) who were receiving GC plus hydroxychloroquine plus an immunosuppressive drug (Merrill et al., 2010; Rovin et al., 2012). However, many open-label studies attest to the efficacy of rituximab in SLE. In addition, there may be patients with lupus nephritis who respond to rituximab infusions in combination with MMF, without additional daily GCs (Beckwith and Lightstone, 2014). Prospective trials are in progress. The US FDA has approved rituximab for non-Hodgkin’s lymphoma, B-cell chronic lymphocytic leukemia, RA, GPA, and microscopic polyangiitis. Adverse reactions include infusion reaction, infections, hypogammaglobulinemia, and late onset neutropenia. A “round” of rituximab which consists of once-a-weekfor-4-weeks or the same total dose given once every 2 weeks during the 4 weeks is approximately $38,000 (not including infusion costs). Some patients maintain improvement for many months or years and do not need a second dose; in many rheumatic disease patients, the round is repeated every 6 months.
Belimumab (Anti-BLyS: Benlysta) Belimumab is a fully human mAB directed against soluble B lymphocyte stimulator protein (BLyS)/B-cell activating factor (also called B cell-activating-factor (BAFF)); hence, it depletes maturing B cells by inhibition of BLyS, which is required for survival and maturation of most B-cell subsets. In 2011, belimumab became the first drug in 50 years to be approved for the treatment of active SLE (excluding patients with active renal or central nervous system (CNS) disease( (Furie et al., 2011; Hahn, 2013; Navarra et al., 2011). Of note, belimumab is meant for lupus patients who are antinuclear antibody or anti-double stranded DNA positive and interestingly showed less response in African-American patients. A recent study showed that responses are durable for a 4-year period—the follow-up period of the study (Merrill et al., 2012). AEs with belimumab include infusion reactions to the IV biologic (a subcutaneous version has just become available in 2017), infections, and depression. To date, blockade of both soluble and cell-bound BLyS and of the April receptor for BlyS plus the BAFF receptor have not been effective and/or safe enough to replace belimumab. The cost of IV belimumab once a month is approximately $4070 (www.goodrx.com, searched on April 2018). Prices were not available at the time of this writing for the subcutaneous form, which will probably come into wide usage.
T-Cell-Targeted Therapies Abatacept (CTLA4-Ig Blocks Second Signals: Orencia) Abatacept (CTLA4-Ig) is a fully human soluble fusion protein that is effective for the treatment of RA. It consists of the extracellular domain of CTLA4 and the Fc portion of IgG1. CTLA4-Ig binds CD80 (B7-1) and
71. TREATMENT OF AUTOIMMUNE DISEASE: ESTABLISHED THERAPIES
CD86 (B7-2) on APCs preventing these molecules from binding to their ligand, CD28, on T cells. This interferes with optimal T-cell activation resulting in decreased production of proinflammatory cytokines (Lenschow et al., 1996). Abatacept is effective, safe and produced statistically significantly less radiographic progression in RA. The US FDA has approved it for use in RA and polyarticular JIA patients who are inadequate responders to DMARDs (Maxwell and Singh, 2010). Abatacept may be used as an alternative to a TNF inhibitor. Abatacept can be administered intravenously every 4 weeks or it can be administered subcutaneously weekly. AEs include infusion reactions, infections, and headache. According to www.goodrx.com searched on April 2018, the monthly cost of abatacept 125 mg subcutaneously weekly is $4200.
OTHER TREATMENT OPTIONS Apremilast (Otezla) Apremilast is an orally available small molecule that specifically targets phosphodiesterase (PDE4) which results in an increased level of cAMP intracellularly in multiple cell types (T cells, mononuclear cells, others). Consequently, the increase in intracellular cAMP decreases the production of several proinflammatory mediators (TNF-α, IL-12, IL-23, IFN-γ, and inducible nitric oxide synthase), and it increases the production of antiinflammatory cytokines (IL-10) (Schafer et al., 2010). This compound is effective in psoriasis and PsA and is US FDA approved for the treatment of active PsA or plaque psoriasis (moderate to severe), and/or PsA (Edwards et al., 2016). Apremilast is started at low dose with titration up to 30 mg twice daily. Modest efficacy has been shown in AS in a double-blind, placebo-controlled unpowered phase II study, but there was no statistical significance (Pathan et al., 2013). Its efficacy was also demonstrated in Behc¸et’s disease (oral and genital ulcers) (Hatemi et al., 2015). The drug is well tolerated with diarrhea, nausea, headache, and weight loss being the most common side effects. No specific lab monitoring is required. The monthly cost of Apremilast at 30 mg bid orally is $3100 according to www.goodrx.com searched on April 2018.
Tofacitinib (Inhibitor of Janus Kinase Activation Pathway: Xeljanz) Tofacitinib is a novel orally administered disease-modifying agent which inhibits Janus kinase (JAK) enzymes, therefore decreasing signaling by a number of cytokine and growth factor receptors, resulting in reduction of a variety of inflammatory mediators. Tofacitinib was shown to be effective and can be used as monotherapy or combined with MTX (our usual approach) or other nonbiologic DMARDs in patients with moderately to severely active RA who have had an inadequate response to MTX (Fleischmann et al., 2012; Kremer et al., 2013). It is taken in a dose of 5 mg twice daily or 11 mg extended release daily. The relative safety of tofacitinib appeared similar to that of other biologic disease modifying agents, including increased risk of infection and abnormal liver function tests. Other side effects include neutropenia, lymphopenia, hyperlipidemia, and, possibly, increased serum creatinine and gastrointestinal perforations. The ACR recommends that tofacitinib be used in patients with RA who have failed to respond adequately to MTX plus a TNF-inhibiting or non-TNF-inhibiting biologic (including abatacept, rituximab, tocilizumab) (Singh et al., 2016). Thus it is not yet viewed as first-line therapy for most patients with RA. Several additional JakStat inhibitors, some more specific for molecules that do not inhibit hematopoiesis, are in development. Baricitinib has recently been approved by the FDA for treatment of RA. According to www.goodrx.com searched on April 2018, the monthly cost of tofacitinib at 5 mg bid orally is $4100.
INTRAVENOUS IMMUNOGLOBULIN The use of intravenous IV immuneglobulin (IVIG) in autoimmune diseases has several possible mechanisms of action in suppression of inflammatory and autoimmune processes, including interference with Fc receptors on effector cells, supply of antiidiotypic antibody activity against serum autoantibodies, inhibition of reticuloendothelial clearance of antibody-covered platelets via Fc receptors, and regulation of expression of proinflammatory cytokines and blockade of adhesion molecules in inflammatory states (Silvergleid and Berger, 2011). In addition, other effects of IVIG include solubilization and clearance of immune complexes, altered T-cell subsets, and increased T regulatory cells. IVIG is useful in a wide range of autoimmune and autoinflammatory diseases such as GuillainBarre´ syndrome, myasthenia gravis, autoimmune peripheral neuropathies, Kawasaki disease,
hematologic conditions such as autoimmune thrombocytopenia, hemolytic anemia or neutropenia, and antibodymediated CNS diseases resulting from interference with neurotransmitter function. Small studies have shown that IVIG is a reasonable second-line therapy for refractory dermatomyositis or polymyositis (Cherin et al., 2002; Dalakas et al., 1993). AEs of IVIG treatment include allergic reactions, including anaphylaxis (particularly in males who are IgA deficient), headache, nausea, chills or flushing, aseptic meningitis, thrombosis, and renal dysfunction. Most of these reactions are mild and transient, reversible events. Serious reactions are rare (Silvergleid and Berger, 2011). According to Epocrates, searched on April 2018, the cost of a single “round” of IV Ig varies from $3500 to $8000, depending on the dose and the supplier. This does not include infusion costs.
COMMENT REGARDING COSTS OF THERAPIES: BIOSIMILARS As shown above, the cost of medications for treatment of a common inflammatory rheumatic disease, RA, can vary from $300 to $5000 per month. All of the recently developed treatments—biologics and small molecules— are on that expensive side. The costs are also quite variable depending on what contract has been made between the payer, the pharmacy provider, and the pharmacy benefits manager companies. Biosimilars have been developed which USA and European oversight bodies have approved for patient use. To date, biosimilars do not differ from the biologic they mimic in efficacy or toxicity (Cohen et al., 2017). Now the question becomes can they be priced to an advantage for the patients and providers—perhaps 30% less in cost? The answer appears complex, with a small number of European countries paying for only one biosimilar and not the original biologic for patients with RA. A recent study from the United Kingdom showed that using infliximab and etanercept biosimilars (in rheumatic diseases) saved the National Health Service 38.8 million pounds over 2 years (Aladel et al., 2017). In the United States, there is friction between choice, profit, and affordability, with some issues being decided in part by the legal system. Somewhere in the not-too-distant future, a compromise will have to be reached that allows care to be increasingly excellent but more affordable for patients, providers, and societies.
MOVING TOWARD MORE BIOLOGICAL AND MOLECULAR THERAPIES Over the past few decades, progressive advancement in our understandings of immunopathogenesis has led to a significant expansion of potential therapeutic targets. This scientific progress has ushered in widespread use of new biologic and molecular treatments specifically targeting B and T cells, costimulation and signal transduction molecules, maturation factors, cytokines, and TLRs on APCs. For example, anti-TNF therapy is now routinely used in RA and seronegative spondyloarthritides, as monotherapy or in combination therapy with traditional DMARDs as discussed above (Singh et al., 2016). Such new therapeutic targets are the subject of the next chapter and continue to improve the standard treatments and outcomes for many autoimmune diseases.
References Afifi, S., Adel, N.G., Devlin, S., et al., 2016. Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study. Bone Marrow Transpl. 51, 546552. Aladel, M.I., Fitzpatrick, R.X., Chapman, S.R., 2017. Impact of infliximab and etanercept biosimilars on biological disease-modifying antirheumatic drugs utilization and NHS budget in the UK. BioDrugs 31, 533544. Al Sawah, S., Zhang, X., Zhu, B., Magder, L.S., Foster, S.A., Iikuni, N., et al., 2015. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort. Lupus Sci. Med. 2 (1), e000066. Available from: https://doi.org/10.1136/lupus-2014-000066. Alarcon, G.S., McGwin, G., Bertoli, A.M., Fessler, B.J., Calvo-Alen, J., Bastian, H.M., et al., 2007. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann. Rheum. Dis. 66 (9), 11681172. Available from: https://doi.org/10.1136/ard.2006.068676. Allison, A.C., Eugui, E.M., 2000. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47 (23), 85118. Amin, A.R., Vyas, P., Attur, M., Leszczynska-Piziak, J., Patel, I.R., Weissmann, G., et al., 1995. The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase. Proc. Natl. Acad. Sci. U.S.A. 92 (17), 79267930. Appel, G.B., Contreras, G., Dooley, M.A., Ginzler, E.M., Isenberg, D., Jayne, D., et al., 2009. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20 (5), 11031112. Available from: https://doi.org/10.1681/ ASN.2008101028. Austin III, H.A., Klippel, J.H., Balow, J.E., le Riche, N.G., Steinberg, A.D., Plotz, P.H., et al., 1986. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N. Engl. J. Med. 314 (10), 614619. Available from: https://doi.org/10.1056/NEJM198603063141004.
71. TREATMENT OF AUTOIMMUNE DISEASE: ESTABLISHED THERAPIES
Baeten, D., Sieper, J., Braun, J., Baraliakos, X., Dougados, M., Emery, P., et al., 2015. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N. Engl. J. Med. 373 (26), 25342548. Available from: https://doi.org/10.1056/NEJMoa1505066. Baker, K.F., Isaacs, J.D., 2017. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann. Rheum. Dis. Available from: https://doi.org/10.1136/annrheumdis-2017-211555. Barile, L., Lavalle, C., 1992. Transverse myelitis in systemic lupus erythematosus—the effect of IV pulse methylprednisolone and cyclophosphamide. J. Rheumatol. 19 (3), 370372. Beckwith, H., Lightstone, L., 2014. Rituximab in systemic lupus erythematosus and lupus nephritis. Nephron Clin. Pract. 128 (34), 250254. Available from: https://doi.org/10.1159/000368585. Blumenfield, M., 1978. Psychological aspects of systemic lupus erythematosus. Prim. Care 5 (1), 159171. Boumpas, D.T., Austin 3rd, H.A., Vaughn, E.M., Klippel, J.H., Steinberg, A.D., Yarboro, C.H., et al., 1992. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340 (8822), 741745. Cade, R., Stein, G., Pickering, M., Schlein, E., Spooner, G., 1976. Low dose, long-term treatment of rheumatoid arthritis with azathioprine. South Med. J. 69 (4), 388392. Calabrese, L.H., Rose-John, S., 2014. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat. Rev. Rheumatol. 10 (12), 720727. Available from: https://doi.org/10.1038/nrrheum.2014.127. Cao, W.W., Kao, P.N., Aoki, Y., Xu, J.C., Shorthouse, R.A., Morris, R.E., 1996. A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2. Transplant. Proc. 28 (6), 30793080. Casciola-Rosen, L.A., Anhalt, G., Rosen, A., 1994. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J. Exp. Med. 179 (4), 13171330. Chan, T.M., Li, F.K., Tang, C.S., Wong, R.W., Fang, G.X., Ji, Y.L., et al., 2000. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med. 343 (16), 11561162. Available from: https:// doi.org/10.1056/NEJM200010193431604. Cherin, P., Pelletier, S., Teixeira, A., Laforet, P., Genereau, T., Simon, A., et al., 2002. Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. 46 (2), 467474. Choi, H.K., Hernan, M.A., Seeger, J.D., Robins, J.M., Wolfe, F., 2002. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359 (9313), 11731177. Available from: https://doi.org/10.1016/S0140-6736(02)08213-2. Cohen, S., Genovese, M.C., Choy, E., Perez-Ruiz, F., Matsumoto, A., Pavelka, K., et al., 2017. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to sveere theumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann. Rheum. Dis. 76, 16791687. Contreras, G., Pardo, V., Leclercq, B., Lenz, O., Tozman, E., O’Nan, P., et al., 2004. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 350 (10), 971980. Available from: https://doi.org/10.1056/NEJMoa031855. Cragg, M.S., Walshe, C.A., Ivanov, A.O., Glennie, M.J., 2005. The biology of CD20 and its potential as a target for mAb therapy. Curr. Dir. Autoimmun. 8, 140174. Available from: https://doi.org/10.1159/000082102. Cronstein, B.N., 1996. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum. 39 (12), 19511960. Dalakas, M.C., Illa, I., Dambrosia, J.M., Soueidan, S.A., Stein, D.P., Otero, C., et al., 1993. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N. Engl. J. Med. 329 (27), 19932000. Available from: https://doi.org/10.1056/ NEJM199312303292704. Dawson, L.J., Caulfield, V.L., Stanbury, J.B., Field, A.E., Christmas, S.E., Smith, P.M., 2005. Hydroxychloroquine therapy in patients with primary Sjogren’s syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology (Oxford) 44 (4), 449455. Available from: https://doi.org/10.1093/rheumatology/keh506. De Groot, K., Rasmussen, N., Bacon, P.A., Tervaert, J.W., Feighery, C., Gregorini, G., et al., 2005. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52 (8), 24612469. Available from: https://doi.org/10.1002/art.21142. Dimitrijevic, M., Bartlett, R.R., 1996. Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of mononuclear cells in rheumatoid arthritis. Transplant. Proc. 28 (6), 30863087. Dooley, M.A., Jayne, D., Ginzler, E.M., Isenberg, D., Olsen, N.J., Wofsy, D., et al., 2011. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N. Engl. J. Med. 365 (20), 18861895. Available from: https://doi.org/10.1056/NEJMoa1014460. Edwards, C.J., Blanco, F.J., Crowley, J., Birbara, C.A., Jaworski, J., Aelion, J., et al., 2016. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann. Rheum. Dis. 75 (6), 10651073. Available from: https://doi.org/10.1136/annrheumdis-2015-207963. Edwards, M.H., Pierangeli, S., Liu, X., Barker, J.H., Anderson, G., Harris, E.N., 1997. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 96 (12), 43804384. Emery, P., Breedveld, F.C., Lemmel, E.M., Kaltwasser, J.P., Dawes, P.T., Gomor, B., et al., 2000. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 39 (6), 655665. Ernst, E., Rose, M., Lee, R., 1984. Modification of transoperative changes in blood fluidity by hydroxychloroquine: a possible explanation for the drug’s antithrombotic effect. Pharmatherapeutica 4 (1), 4852. Feldman, S.R., 2017. Treatment of Psoriasis in Adults. UpToDateRetrieved from . Available from: http://www.uptodate.com/home. Fischer, A., Brown, K.K., Du Bois, R.M., Frankel, S.K., Cosgrove, G.P., Fernandez-Perez, E.R., et al., 2013. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J. Rheumatol. 40 (5), 640646. Available from: https://doi. org/10.3899/jrheum.121043. Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C.A., Bradley, J.D., et al., 2012. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 367 (6), 495507. Available from: https://doi.org/10.1056/NEJMoa1109071. Fox, R.I., 1993. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin. Arthritis Rheum. 23 (2 Suppl 1), 8291.
Fox, R.I., 1998. Mechanism of action of leflunomide in rheumatoid arthritis. J. Rheumatol. Suppl 53, 2026. Fox, D.A., McCune, W.J., 1994. Immunosuppressive drug therapy of systemic lupus erythematosus. Rheum. Dis. Clin. N. Am. 20 (1), 265299. Fox, R.I., Kang, H.I., 1993. Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation. Lupus (2 Suppl 1), S912. Furie, R., Petri, M., Zamani, O., Cervera, R., Wallace, D.J., Tegzova, D., et al., 2011. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63 (12), 39183930. Available from: https://doi.org/10.1002/art.30613. Galindo-Rodriguez, G., Avina-Zubieta, J.A., Pizarro, S., Diaz de Leon, V., Saucedo, N., Fuentes, M., et al., 1999. Cyclophosphamide pulse therapy in optic neuritis due to systemic lupus erythematosus: an open trial. Am. J. Med. 106 (1), 6569. Genestier, L., Paillot, R., Fournel, S., Ferraro, C., Miossec, P., Revillard, J.P., 1998. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J. Clin. Invest. 102 (2), 322328. Available from: https://doi.org/10.1172/JCI2676. Ghaussy, N.O., Sibbitt Jr., W.L., Qualls, C.R., 2001. Cigarette smoking, alcohol consumption, and the risk of systemic lupus erythematosus: a case-control study. J. Rheumatol. 28 (11), 24492453. Ginzler, E.M., Dooley, M.A., Aranow, C., Kim, M.Y., Buyon, J., Merrill, J.T., et al., 2005. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353 (21), 22192228. Available from: https://doi.org/10.1056/NEJMoa043731. Ginzler, E.M., Wofsy, D., Isenberg, D., Gordon, C., Lisk, L., Dooley, M.A., et al., 2010. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum. 62 (1), 211221. Available from: https://doi.org/10.1002/art.25052. Goekoop-Ruiterman, Y.P., de Vries-Bouwstra, J.K., Allaart, C.F., van Zeben, D., Kerstens, P.J., Hazes, J.M., et al., 2005. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52 (11), 33813390. Available from: https://doi.org/10.1002/art.21405. Goekoop-Ruiterman, Y.P., de Vries-Bouwstra, J.K., Allaart, C.F., van Zeben, D., Kerstens, P.J., Hazes, J.M., et al., 2007. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 146 (6), 406415. Gonzalez-Lopez, L., Gamez-Nava, J.I., Jhangri, G., Russell, A.S., Suarez-Almazor, M.E., 2000. Decreased progression to rheumatoid arthritis or other connective tissue diseases in patients with palindromic rheumatism treated with antimalarials. J. Rheumatol. 27 (1), 4146. Gourley, M.F., Austin III., H.A., Scott, D., Yarboro, C.H., Vaughan, E.M., Muir, J., et al., 1996. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann. Intern. Med. 125 (7), 549557. Greco, C.M., Rudy, T.E., Manzi, S., 2004. Effects of a stress-reduction program on psychological function, pain, and physical function of systemic lupus erythematosus patients: a randomized controlled trial. Arthritis Rheum. 51 (4), 625634. Available from: https://doi.org/ 10.1002/art.20533. Grigor, C., Capell, H., Stirling, A., McMahon, A.D., Lock, P., Vallance, R., et al., 2004. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364 (9430), 263269. Available from: https://doi.org/ 10.1016/S0140-6736(04)16676-2. Grisar, J., Aringer, M., Koller, M.D., Stummvoll, G.H., Eselbock, D., Zwolfer, B., et al., 2004. Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells. Ann. Rheum. Dis. 63 (12), 16321637. Available from: https://doi.org/10.1136/ard.2003.018440. Gul, A., Ozdogan, H., Erer, B., Ugurlu, S., Kasapcopur, O., Davis, N., et al., 2015. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res. Ther. 17, 243. Available from: https://doi.org/10.1186/s13075-0150765-4. Hahn, B.H., 2013. Belimumab for systemic lupus erythematosus. N. Engl. J. Med. 368 (16), 15281535. Available from: https://doi.org/ 10.1056/NEJMct1207259. Hahn, B.H., McMahon, M.A., Wilkinson, A., Wallace, W.D., Daikh, D.I., Fitzgerald, J.D., et al., 2012. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. (Hoboken) 64 (6), 797808. Available from: https:// doi.org/10.1002/acr.21664. Harris Jr., R.C., 2002. Cyclooxygenase-2 inhibition and renal physiology. Am. J. Cardiol. 89 (6A), 10D17D. Hashkes, P.J., Spalding, S.J., Giannini, E.H., Huang, B., Johnson, A., Park, G., et al., 2012. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann. Intern. Med. 157 (8), 533541. Available from: https://doi.org/10.7326/0003-4819-157-8201210160-00003. Hatemi, G., Melikoglu, M., Tunc, R., Korkmaz, C., Turgut Ozturk, B., Mat, C., et al., 2015. Apremilast for Behcet’s syndrome—a phase 2, placebo-controlled study. N. Engl. J. Med. 372 (16), 15101518. Available from: https://doi.org/10.1056/NEJMoa1408684. Hazlewood, G.S., Barnabe, C., Tomlinson, G., Marshall, D., Devoe, D., Bombardier, C., 2016. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ 353, i1777. Available from: https://doi.org/10.1136/bmj.i1777. Hirohata, S., Ohshima, N., Yanagida, T., Aramaki, K., 2002. Regulation of human B cell function by sulfasalazine and its metabolites. Int. Immunopharmacol. 2 (5), 631640. Hoffman, G.S., Cid, M.C., Hellmann, D.B., Guillevin, L., Stone, J.H., Schousboe, J., et al., 2002. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 46 (5), 13091318. Available from: https://doi.org/10.1002/art.10262. Houssiau, F.A., 2016. Moving East: the Euro-Lupus Nephritis regimen in Asia. Kidney Int. 89 (1), 2527. Available from: https://doi.org/ 10.1016/j.kint.2015.11.003. Houssiau, F.A., Vasconcelos, C., D’Cruz, D., Sebastiani, G.D., Garrido Ed Ede, R., Danieli, M.G., et al., 2002. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 46 (8), 21212131. Available from: https://doi.org/10.1002/art.10461. Houssiau, F.A., D’Cruz, D., Sangle, S., Remy, P., Vasconcelos, C., Petrovic, R., et al., 2010a. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann. Rheum. Dis. 69 (12), 20832089. Available from: https://doi.org/10.1136/ard.2010.131995.
71. TREATMENT OF AUTOIMMUNE DISEASE: ESTABLISHED THERAPIES
Houssiau, F.A., Vasconcelos, C., D’Cruz, D., Sebastiani, G.D., de Ramon Garrido, E., Danieli, M.G., et al., 2010b. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann. Rheum. Dis. 69 (1), 6164. Available from: https://doi.org/10.1136/ard.2008.102533. Hu, W., Liu, Z., Chen, H., Tang, Z., Wang, Q., Shen, K., et al., 2002. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin. Med. J. (Engl.) 115 (5), 705709. Illei, G.G., Austin, H.A., Crane, M., Collins, L., Gourley, M.F., Yarboro, C.H., et al., 2001. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann. Intern. Med. 135 (4), 248257. Isenberg, D., Appel, G.B., Contreras, G., Dooley, M.A., Ginzler, E.M., Jayne, D., et al., 2010. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 49 (1), 128140. Available from: https://doi.org/10.1093/rheumatology/ kep346. Izmirly, P.M., Kim, M.Y., Llanos, C., Le, P.U., Guerra, M.M., Askanase, A.D., et al., 2010. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann. Rheum. Dis. 69 (10), 18271830. Available from: https://doi.org/10.1136/ard.2009.119263. Jancinova, V., Nosal, R., Petrikova, M., 1994. On the inhibitory effect of chloroquine on blood platelet aggregation. Thromb. Res. 74 (5), 495504. Jones, S.K., 1992. Ultraviolet radiation (UVR) induces cell-surface Ro/SSA antigen expression by human keratinocytes in vitro: a possible mechanism for the UVR induction of cutaneous lupus lesions. Br. J. Dermatol. 126 (6), 546553. Jones, G., Sebba, A., Gu, J., Lowenstein, M.B., Calvo, A., Gomez-Reino, J.J., et al., 2010a. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann. Rheum. Dis. 69 (1), 8896. Available from: https://doi.org/10.1136/ard.2008.105197. Jones, R.B., Tervaert, J.W., Hauser, T., Luqmani, R., Morgan, M.D., Peh, C.A., et al., 2010. Rituximab versus cyclophosphamide in ANCAassociated renal vasculitis. N. Engl. J. Med. 363 (3), 211220. Available from: https://doi.org/10.1056/NEJMoa0909169. Jover, J.A., Hernandez-Garcia, C., Morado, I.C., Vargas, E., Banares, A., Fernandez-Gutierrez, B., 2001. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 134 (2), 106114. King, J.K., Hahn, B.H., 2007. Systemic lupus erythematosus: modern strategies for management: a moving target. Best Pract. Res. Clin. Rheumatol. 21 (6), 971987. Available from: https://doi.org/10.1016/j.berh.2007.09.002. Kirouka, B.D., 2007. Systemic glucocorticoid therapy in systemic lupus erythematosus. In: Wallace, D.J., Hahn, B.H. (Eds.), Dubois’ Lupus Erythematosus, 7th ed. Lippincott Williams and Wilkins, Philadelphia, PA. Klareskog, L., Stolt, P., Lundberg, K., Kallberg, H., Bengtsson, C., Grunewald, J., et al., 2006. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 54 (1), 3846. Available from: https://doi.org/10.1002/art.21575. Kovacs, B., Lafferty, T.L., Brent, L.H., DeHoratius, R.J., 2000. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann. Rheum. Dis. 59 (2), 120124. Kremer, J., Li, Z.G., Hall, S., Fleischmann, R., Genovese, M., Martin-Mola, E., et al., 2013. Tofacitinib in combination with nonbiologic diseasemodifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 159 (4), 253261. Available from: https://doi.org/10.7326/0003-4819-159-4-201308200-00006. Kyburz, D., Brentano, F., Gay, S., 2006. Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling. Nat. Clin. Pract. Rheumatol. 2 (9), 458459. Available from: https://doi.org/10.1038/ncprheum0292. Lee, C.K., Lee, E.Y., Chung, S.M., Mun, S.H., Yoo, B., Moon, H.B., 2004. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. Arthritis Rheum. 50 (12), 38313843. Available from: https://doi.org/10.1002/art.20637. Lee, Y.H., Lee, H.S., Choi, S.J., Dai Ji, J., Song, G.G., 2011. Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials. Lupus 20 (6), 636640. Available from: https://doi.org/10.1177/0961203310389486. Lenschow, D.J., Walunas, T.L., Bluestone, J.A., 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14, 233258. Available from: https://doi.org/10.1146/annurev.immunol.14.1.233. Li, X., Ren, H., Zhang, Q., Zhang, W., Wu, X., Xu, Y., et al., 2012. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol. Dial. Transplant. 27 (4), 14671472. Available from: https://doi. org/10.1093/ndt/gfr484. Liu, Z., Zhang, H., Liu, Z., Xing, C., Fu, P., Ni, Z., et al., 2015. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann. Intern. Med. 162 (1), 1826. Available from: https://doi.org/10.7326/M14-1030. Lu, X., Xie, W., Reed, D., Bradshaw, W.S., Simmons, D.L., 1995. Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 92 (17), 79617965. MacDermott, R.P., 2017. Treatment of Ulcerative Colitis. UpToDateRetrieved from . Available from: http://www.uptodate.com/home. Magee, C., 2012. In: Furst, D.E., Romain, P.L. (Eds.), Pharmacology and Side Effects of Cyclosporine and Tacrolimus. UpToDate, Retrieved from http://www.uptodate.com/home. Mahid, S.S., Minor, K.S., Soto, R.E., Hornung, C.A., Galandiuk, S., 2006. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin. Proc. 81 (11), 14621471. Available from: https://doi.org/10.4065/81.11.1462. Maldonado-Ficco, H., Perez-Alamino, R., Maldonado-Cocco, J.A., 2016. Secukinumab: a promising therapeutic option in spondyloarthritis. Clin. Rheumatol. 35 (9), 21512161. Available from: https://doi.org/10.1007/s10067-016-3350-6. Manna, S.K., Aggarwal, B.B., 1999. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J. Immunol. 162 (4), 20952102. Marmor, M.F., Kellner, U., Lai, T.Y., Lyons, J.S., Mieler, W.F., American Academy of, O, 2011. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 118 (2), 415422. Available from: https://doi.org/10.1016/j. ophtha.2010.11.017.
Maxwell, L.J., Singh, J.A., 2010. Abatacept for rheumatoid arthritis: a Cochrane systematic review. J. Rheumatol. 37 (2), 234245. Available from: https://doi.org/10.3899/jrheum.091066. McCune, W.J., Fox, D., 1989. Intravenous cyclophosphamide therapy of severe SLE. Rheum. Dis. Clin. N. Am. 15 (3), 455477. McInnes, I.B., Kavanaugh, A., Gottlieb, A.B., Puig, L., Rahman, P., Ritchlin, C., et al., 2013. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382 (9894), 780789. Available from: https://doi.org/10.1016/S0140-6736(13)60594-2. McInnes, I.B., Mease, P.J., Kirkham, B., Kavanaugh, A., Ritchlin, C.T., Rahman, P., et al., 2015. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386 (9999), 11371146. Available from: https://doi.org/10.1016/S0140-6736(15)61134-5. Mello, S.B., Barros, D.M., Silva, A.S., Laurindo, I.M., Novaes, G.S., 2000. Methotrexate as a preferential cyclooxygenase 2 inhibitor in whole blood of patients with rheumatoid arthritis. Rheumatology (Oxford) 39 (5), 533536. Merrill, J.T., Neuwelt, C.M., Wallace, D.J., Shanahan, J.C., Latinis, K.M., Oates, J.C., et al., 2010. Efficacy and safety of rituximab in moderatelyto-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62 (1), 222233. Available from: https://doi.org/10.1002/art.27233. Merrill, J.T., Ginzler, E.M., Wallace, D.J., McKay, J.D., Lisse, J.R., Aranow, C., et al., 2012. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum. 64 (10), 33643373. Available from: https://doi.org/10.1002/ art.34564. Morabito, L., Montesinos, M.C., Schreibman, D.M., Balter, L., Thompson, L.F., Resta, R., et al., 1998. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-50 -nucleotidase-mediated conversion of adenine nucleotides. J. Clin. Invest. 101 (2), 295300. Available from: https://doi.org/10.1172/JCI1554. Morganroth, P.A., Kreider, M.E., Werth, V.P., 2010. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res. (Hoboken) 62 (10), 14961501. Available from: https://doi.org/10.1002/acr.20212. Mottonen, T., Hannonen, P., Leirisalo-Repo, M., Nissila, M., Kautiainen, H., Korpela, M., et al., 1999. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 353 (9164), 15681573. Mukhtyar, C., Guillevin, L., Cid, M.C., Dasgupta, B., de Groot, K., Gross, W., et al., 2009. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann. Rheum. Dis. 68 (3), 310317. Available from: https://doi.org/10.1136/ard.2008.088096. Navarra, S.V., Guzman, R.M., Gallacher, A.E., Hall, S., Levy, R.A., Jimenez, R.E., et al., 2011. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377 (9767), 721731. Available from: https:// doi.org/10.1016/S0140-6736(10)61354-2. Navarro-Millan, I., Singh, J.A., Curtis, J.R., 2012. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin. Ther. 34 (4), 788802. Available from: https://doi.org/10.1016/j.clinthera.2012.02.014. e783. Neuwelt, C.M., Lacks, S., Kaye, B.R., Ellman, J.B., Borenstein, D.G., 1995. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am. J. Med. 98 (1), 3241. Available from: https://doi.org/10.1016/S0002-9343(99)80078-3. Nigrovic, P.A., Mannion, M., Prince, F.H., Zeft, A., Rabinovich, C.E., van Rossum, M.A., et al., 2011. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 63 (2), 545555. Available from: https://doi.org/10.1002/art.30128. O’Dell, J.R., Haire, C.E., Erikson, N., Drymalski, W., Palmer, W., Eckhoff, P.J., et al., 1996. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N. Engl. J. Med. 334 (20), 12871291. Available from: https://doi.org/10.1056/NEJM199605163342002. Ostensen, M., 2017. Sexual and reproductive health in rheumatic disease. Nat. Rev. Rheumatol. 13 (8), 485493. Available from: https://doi. org/10.1038/nrrheum.2017.102. Otto, R., Mackay, I.R., 1967. Psycho-social and emotional disturbance in systemic lupus erythematosus. Med. J. Aust. 2 (11), 488493. Padyukov, L., Silva, C., Stolt, P., Alfredsson, L., Klareskog, L., 2004. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum. 50 (10), 30853092. Available from: https:// doi.org/10.1002/art.20553. Pagnoux, C., Mahr, A., Hamidou, M.A., Boffa, J.J., Ruivard, M., Ducroix, J.P., et al., 2008. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N. Engl. J. Med. 359 (26), 27902803. Available from: https://doi.org/10.1056/NEJMoa0802311. Papp, K., Bissonnette, R., Rosoph, L., Wasel, N., Lynde, C.W., Searles, G., et al., 2008. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet 371 (9621), 13371342. Available from: https://doi.org/10.1016/ S0140-6736(08)60593-0. Pathan, E., Abraham, S., Van Rossen, E., Withrington, R., Keat, A., Charles, P.J., et al., 2013. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann. Rheum. Dis. 72 (9), 14751480. Available from: https://doi.org/10.1136/annrheumdis-2012-201915. Prefontaine, E., Sutherland, L.R., Macdonald, J.K., Cepoiu, M., 2009. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev. (1), CD000067. Available from: https://doi.org/10.1002/14651858.CD000067.pub2. Rantalaiho, V., Korpela, M., Hannonen, P., Kautiainen, H., Jarvenpaa, S., Leirisalo-Repo, M., et al., 2009. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum. 60 (5), 12221231. Available from: https://doi.org/10.1002/art.24447. Regius, O., Lengyel, E., Borzsonyi, L., Beregi, E., 1988. The effect of smoking on the presence of antinuclear antibodies and on the morphology of lymphocytes in aged subjects. Z. Gerontol. 21 (3), 161163. Ribi, C., Cohen, P., Pagnoux, C., Mahr, A., Arene, J.P., Puechal, X., et al., 2010. Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients. Arthritis Rheum. 62 (4), 11861197. Available from: https://doi.org/10.1002/art.27340. Rich, E., Moreland, L.W., Alarcon, G.S., 1999. Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug. J. Rheumatol. 26 (2), 259261.
71. TREATMENT OF AUTOIMMUNE DISEASE: ESTABLISHED THERAPIES
Rodenburg, R.J., Ganga, A., van Lent, P.L., van de Putte, L.B., van Venrooij, W.J., 2000. The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis. Arthritis Rheum. 43 (9), 19411950. Available from: https://doi. org/10.1002/1529-0131(200009)43:9 , 1941::AID-ANR4 . 3.0.CO;2-O. Rovin, B.H., Furie, R., Latinis, K., Looney, R.J., Fervenza, F.C., Sanchez-Guerrero, J., et al., 2012. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64 (4), 12151226. Available from: https://doi.org/10.1002/art.34359. Saag, K., et al., 2011. Systemic glucocorticoid therapy in rheumatology, Rheumatology, 5th ed. Mosby Elsevier, Philadelphia, PA. Saag, K.G., Cerhan, J.R., Kolluri, S., Ohashi, K., Hunninghake, G.W., Schwartz, D.A., 1997. Cigarette smoking and rheumatoid arthritis severity. Ann. Rheum. Dis. 56 (8), 463469. Salmi, M., Rajala, P., Jalkanen, S., 1997. Homing of mucosal leukocytes to joints. Distinct endothelial ligands in synovium mediate leukocytesubtype specific adhesion. J. Clin. Invest. 99 (9), 21652172. Available from: https://doi.org/10.1172/JCI119389. Sands, K., Jansen, R., Zaslau, S., Greenwald, D., 2015. Review article: the safety of therapeutic drugs in male inflammatory bowel disease patients wishing to conceive. Aliment. Pharmacol. Ther. 41 (9), 821834. Available from: https://doi.org/10.1111/apt.13142. Schafer, P.H., Parton, A., Gandhi, A.K., Capone, L., Adams, M., Wu, L., et al., 2010. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br. J. Pharmacol. 159 (4), 842855. Available from: https:// doi.org/10.1111/j.1476-5381.2009.00559.x. Schreiber, S.L., Crabtree, G.R., 1992. The mechanism of action of cyclosporin A and FK506. Immunol. Today 13 (4), 136142. Available from: https://doi.org/10.1016/0167-5699(92)90111-J. Schultz, C., 2013. Voclosporin as a treatment for noninfectious uveitis. Ophthalmol Eye Dis. 5, 510. Available from: https://doi.org/10.4137/ OED.S7995. Schur, P.H., 2017. Randomized Clinical Trails of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis. UpToDate, Retrieved from http:// www.uptodate.com/home. Scott, D.G., Bacon, P.A., 1984. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am. J. Med. 76 (3), 377384. Seitz, M., Zwicker, M., Wider, B., 2001. Enhanced in vitro induced production of interleukin 10 by peripheral blood mononuclear cells in rheumatoid arthritis is associated with clinical response to methotrexate treatment. J. Rheumatol. 28 (3), 496501. Siemasko, K., Chong, A.S., Jack, H.M., Gong, H., Williams, J.W., Finnegan, A., 1998. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J. Immunol. 160 (4), 15811588. Silvergleid, A.J., Berger, M., 2011. In: Schrier, S.L., Stiehm, E.R., Tirnauer, J.S., Feldweg, A.M. (Eds.), General Principles in the Use of Immune Globulin. UpToDate, Retrieved from http://www.uptodate.com/home. Singh, J.A., Christensen, R., Wells, G.A., Suarez-Almazor, M.E., Buchbinder, R., Lopez-Olivo, M.A., et al., 2009. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 181 (11), 787796. Available from: https:// doi.org/10.1503/cmaj.091391. Singh, J.A., Beg, S., Lopez-Olivo, M.A., 2011. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J. Rheumatol. 38 (1), 1020. Available from: https://doi.org/10.3899/jrheum.100717. Singh, J.A., Saag, K.G., Bridges Jr., S.L., Akl, E.A., Bannuru, R.R., Sullivan, M.C., et al., 2016. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. (Hoboken) 68 (1), 125. Available from: https://doi.org/10.1002/ acr.22783. Smolen, J.S., Kalden, J.R., Scott, D.L., Rozman, B., Kvien, T.K., Larsen, A., et al., 1999. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353 (9149), 259266. So, A., De Smedt, T., Revaz, S., Tschopp, J., 2007. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9 (2), R28. Available from: https://doi.org/10.1186/ar2143. Solomon, D., 2012. In: Furst, D.E., Romain, P.L. (Eds.), Nonselective NSAIDs: Overview of Adverse Effects. UpToDate, Retrieved from http:// www.uptodate.com/home. Stone, J.H., 2010. General principles of the use of cyclophosphamide in rheumatic and renal diseaseIn: Furst, D.E., Ramirez, M.P. (Eds.), UpToDate, Retrieved from http://www.uptodate.com/home. Stone, J.H., Merkel, P.A., Spiera, R., Seo, P., Langford, C.A., Hoffman, G.S., et al., 2010. Rituximab versus cyclophosphamide for ANCAassociated vasculitis. N. Engl. J. Med. 363 (3), 221232. Available from: https://doi.org/10.1056/NEJMoa0909905. Stone, J.H., Tuckwell, K., Dimonaco, S., Klearman, M., Aringer, M., Blockmans, D., et al., 2017. Trial of tocilizumab in giant-cell arteritis. N. Engl. J. Med. 377 (4), 317328. Available from: https://doi.org/10.1056/NEJMoa1613849. Tashkin, D.P., Elashoff, R., Clements, P.J., Goldin, J., Roth, M.D., Furst, D.E., et al., 2006. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 354 (25), 26552666. Available from: https://doi.org/10.1056/NEJMoa055120. Tashkin, D.P., Roth, M.D., Clements, P.J., Furst, D.E., Khanna, D., Kleerup, E.C., et al., 2016. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir. Med. 4 (9), 708719. Available from: https://doi.org/10.1016/S2213-2600(16)30152-7. Taylor, P.C., 2010. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr. Opin. Pharmacol. 10 (3), 308315. Available from: https://doi.org/10.1016/j.coph.2010.01.005. Timmer, A., McDonald, J.W., Macdonald, J.K., 2007. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. (1), CD000478. Available from: https://doi.org/10.1002/14651858.CD000478.pub2. Timmerman, L.A., Clipstone, N.A., Ho, S.N., Northrop, J.P., Crabtree, G.R., 1996. Rapid shuttling of NF-AT in discrimination of Ca21 signals and immunosuppression. Nature 383 (6603), 837840. Available from: https://doi.org/10.1038/383837a0. Tobin, M.V., Logan, R.F., Langman, M.J., McConnell, R.B., Gilmore, I.T., 1987. Cigarette smoking and inflammatory bowel disease. Gastroenterology 93 (2), 316321.
Touma, Z., Gladman, D.D., Urowitz, M.B., Beyene, J., Uleryk, E.M., Shah, P.S., 2011. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J. Rheumatol. 38 (1), 6978. Available from: https://doi.org/10.3899/jrheum.100130. Tsokos, G.C., 2004. B cells, be gone—B-cell depletion in the treatment of rheumatoid arthritis. N. Engl. J. Med. 350 (25), 25462548. Available from: https://doi.org/10.1056/NEJMp048114. Urowitz, M.B., Gordon, D.A., Smythe, H.A., Pruzanski, W., Ogryzio, M.A., 1973. Azathioprine in rheumatoid arthritis. A double-blind, cross over study. Arthritis Rheum. 16 (3), 411418. van der Hilst, J., Moutschen, M., Messiaen, P.E., Lauwerys, B.R., Vanderschueren, S., 2016. Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics 10, 7580. Available from: https://doi.org/10.2147/BTT.S102954. Vastert, S.J., de Jager, W., Noordman, B.J., Holzinger, D., Kuis, W., Prakken, B.J., et al., 2014. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 66 (4), 10341043. Available from: https://doi.org/10.1002/art.38296. Von Feldt, J.M., 1995. Systemic lupus erythematosus. Recognizing its various presentations. Postgrad. Med. 97 (4), 79. 83, 86 passim. Wahl, C., Liptay, S., Adler, G., Schmid, R.M., 1998. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J. Clin. Invest. 101 (5), 11631174. Available from: https://doi.org/10.1172/JCI992. Wallace, D.J., 2007. Antimalarial therapies. In: Wallace, D.J., Hahn, B.H. (Eds.), Dubois’ Lupus Erythematousus, 7th ed. Lippincot Williams and Wilkins, Philadelphia, PA. Wang, S., Li, X., Qu, L., Wang, R., Chen, Y., Li, Q., et al., 2012. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study. Lupus 21 (9), 10251035. Available from: https://doi.org/ 10.1177/0961203312448105. Wasko, M.C., Hubert, H.B., Lingala, V.B., Elliott, J.R., Luggen, M.E., Fries, J.F., et al., 2007. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 298 (2), 187193. Available from: https://doi.org/10.1001/jama.298.2.187. Weinblatt, M.E., 2013. Methotrexate in rheumatoid arthritis: a quarter century of development. Trans. Am. Clin. Climatol. Assoc. 124, 1625. Weinblatt, M.E., Weissman, B.N., Holdsworth, D.E., Fraser, P.A., Maier, A.L., Falchuk, K.R., et al., 1992. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum. 35 (2), 129137. Weinblatt, M.E., Kaplan, H., Germain, B.F., Block, S., Solomon, S.D., Merriman, R.C., et al., 1994. Methotrexate in rheumatoid arthritis. A fiveyear prospective multicenter study. Arthritis Rheum. 37 (10), 14921498. Weisman, M.H., Rinaldi, R.Z., 2017. Sulfasalazine in the Treatment of Rheumatoid Arthritis. UpToDate, Retrieved from http://www.uptodate.com/home. Wiederrecht, G., Lam, E., Hung, S., Martin, M., Sigal, N., 1993. The mechanism of action of FK-506 and cyclosporin A. Ann. N.Y. Acad. Sci. 696, 919. Wilke, W.S., 2010. In: Furst, D.E., Romain, P.L. (Eds.), Pharmacology and Side Effects of Azathioprine When Used in Rheumatic Disease. UpToDate, Retrieved from http://www.uptodate.com/home. Willrich, M.A., Murray, D.L., Snyder, M.R., 2015. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. Transl. Res. 165 (2), 270282. Available from: https://doi.org/10.1016/j.trsl.2014.09.006. Wolfe, F., 2000. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J. Rheumatol. 27 (3), 630637. Woodland, J., Chaput de Saintonge, D.M., Evans, S.J., Sharman, V.L., Currey, H.L., 1981. Azathioprine in rheumatoid arthritis: double-blind study of full versus half doses versus placebo. Ann. Rheum. Dis. 40 (4), 355359. Yeilding, N., Szapary, P., Brodmerkel, C., Benson, J., Plotnick, M., Zhou, H., et al., 2012. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives—an update. Ann. N.Y. Acad. Sci. 1263, 112. Available from: https://doi.org/10.1111/ j.1749-6632.2012.06670.x. Zhang, X., Brunner, T., Carter, L., Dutton, R.W., Rogers, P., Bradley, L., et al., 1997. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J. Exp. Med. 185 (10), 18371849.